Good afternoon and welcome to the Trevi Therapeutics3rd Quarter, 2024 earnings conference call. At this time, all participants will be in listen-only mode. (Operator Instruction) Please note this ...
Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in ...
Then she added with emphasis, “This is something I really want to stress: if you’re dealing with a serious condition like cancer, especially, your cough just won’t go away. It will persist, no matter ...